Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
January 22, 2019

EC approves Vertex’s CF treatment Orkambi for children aged two to five years

Vertex Pharmaceuticals (Europe) has secured approval from the European Commission (EC) for Orkambi (lumacaftor/ivacaftor) to treat of children with cystic fibrosis (CF) aged two to five years old who have two copies of the F508del mutation.

Image: Clubbing of the fingers is a classic feature of cystic fibrosis. Photo: courtesy of Jerry Nick, M.D.